Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study

Z. Tian Hengyu Li Yujun Deng H. Yao Ying Wang Liang Jin H. Deng Nabei Chen Jieqiong Liu

DOI PubMed Semantic Scholar